Cyberonics to Participate in 2011 Credit Suisse Small and Mid Cap & Future of Energy Conference

HOUSTON, Sept. 13, 2011 /PRNewswire/ -- Cyberonics, Inc. (NASDAQ: CYBX), a global leader in epilepsy management, today announced it will participate in the 2011 Credit Suisse Small and Mid Cap & Future of Energy Conference on Tuesday, September 27, 2011, in New York.

Greg Browne, Cyberonics' Senior Vice President and Chief Financial Officer, will speak to the attendees of the conference at 10:40 AM Eastern Time.  This session will not be webcast.  Presentation materials can be accessed by clicking on the Investor Relations link on the Cyberonics home page at http://www.cyberonics.com on September 27, 2011.

About Cyberonics, Inc. and the VNS Therapy® System

Cyberonics, Inc. is a medical technology company with core expertise in neuromodulation.  The company developed and markets the VNS Therapy System, which is FDA-approved for the treatment of refractory epilepsy and treatment-resistant depression.  The VNS Therapy System uses a surgically implanted medical device that delivers electrical pulsed signals to the vagus nerve.  Cyberonics markets the VNS Therapy System in selected markets worldwide.

Additional information on Cyberonics and the VNS Therapy System is available at www.cyberonics.com.

Contact information

Greg Browne, CFO
Cyberonics, Inc.
100 Cyberonics Blvd.
Houston, TX 77058
Main:  (281) 228-7262
Fax:  (281) 218-9332
[email protected]

SOURCE Cyberonics, Inc.

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.